EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of a post partum bleeding complication with recombinant factor VIIa



Treatment of a post partum bleeding complication with recombinant factor VIIa



Blood 98(11 Part 2): 80b, November 16



Introduction: A 31-year-old nulliparous woman with a triplet gestation and a beginning HELLP-syndrome (platelets 90/nl, GOT 58U/l) was delivered of healthy triplets by Cesarean section at 34 weeks gestation. Initially the post partum course was uneventful, platelets promptly rose to 150/nl and transaminases dropped. 8 hours post partum, the patient was transferred to the anesthesiologic ICU because of hyperkalemia (7.1 mmol/l). Course: Upon arrival in the ICU, the patient showed the signs of hemorrhagic shock and under the full picture of atonic uterine bleeding, the patient was promply hysterectomized. However, uncontrollable bleeding from drainages and oozing from all tissues during re-laparotomies (total of 8) persisted. 40 hours after hysterectomy, the patient had received a total of 54 PRBC's, 50 FFP's and 7 platelet concentrates. Therapy with rFVIIa was begun. Results: The lab work-up showed anemia, thrombocytopenia and persistent D-dimers, other coagulation parameters (factor activities) were within normal limits. Platelet concentrates prior to the administration of rFVIIa had not shown a sign increase in thrombocytes. However, after rFVIIa was given, a prompt increase in platelet count was observed. Bleeding from drainages was reduced, transfusion needs became significantly less and hematocrit and hemoglobin were stabilized. Outcome: Unfortunately, despite this threapy, the patient developed MOF and died on post partum day 9. Discussion/Conclusion: After hysterecetomy, diffuse bleeding persisted and mass transfusion became necessary. The patient did not have the typical signs of DIC except for increased D-dimers. All other factor concentrations were within normal limits. 2 days after hysterectomy, experimental therapy with rFVIIa was begun. However, it was obviously too late to save the patient's life, since other cascades leading to MOF had already been initiated. Possibly, an earlier and more frequent administration of recombinant factor VIIa could have saved the patient's life.

(PDF 0-2 workdays service: $29.90)

Accession: 035980685

Download citation: RISBibTeXText



Related references

Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient. British Journal of Anaesthesia 93(2): 298-300, 2004

Major post-partum hemorrhage and treatment with recombinant factor VIIa. Anesthesia and Analgesia 101(6): 1886-1887, 2005

Successful treatment of severe retro-peritoneal bleeding with recombinant factor VIIa in women with placenta percreta invading into the left broad ligament: unusual repeated ante-partum intra-abdominal bleeding. Journal of Obstetrics and Gynaecology Research 36(1): 183-186, 2010

Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Canadian Journal of Anaesthesia 50(6): 599-602, 2003

Use of recombinant factor VIIa in massive post-partum haemorrhage. European Journal of Anaesthesiology 25(4): 293-298, 2008

Recombinant factor VIIa for life-threatening post-partum haemorrhage. British Journal of Anaesthesia 95(4): 558; Author Reply 558-558; Author Reply 558, 2005

Recombinant factor VIIa for life-threatening post-partum haemorrhage. British Journal of Anaesthesia 94(5): 592-595, 2005

Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium. North American Journal of Medical Sciences 4(4): 157-162, 2012

Guidelines for use of recombinant factor VIIa in life-threatening post-partum haemorrhage. International Journal of Obstetric Anesthesia 16(3): 299-300; Author Reply 300, 2007

Successful treatment of severe post-partum bleeding after caesarean section using recombinant activated factor VII. Ceska Gynekologie 70(2): 144, 146-8, 2005

Recombinant factor VIIa for intraoperative bleeding in a child with hepatoblastoma and review of recombinant activated factor VIIa use in children undergoing surgery. Journal of Pediatric Surgery 43(4): E15-E19, 2008

Recombinant factor VIIa: use in fatal post partum hemorrhage - Indian experience case series and review of literature. Indian Journal of Hematology & Blood Transfusion 25(1): 1-5, 2009

Recombinant factor VIIa in the treatment of bleeding. American Journal of Clinical Pathology 121(1): 124-137, 2004

Recombinant factor VIIa in the treatment of non-hemophiliac bleeding. Annals of PharmacoTherapy 39(5): 885-891, 2005

The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 104(13): 3858-3864, 2004